Impact of tumor-treating fields on the survival of Japanese patients with newly diagnosed glioblastoma: A multicenter, retrospective cohort study

被引：0

作者：

Kanamori, Masayuki ^{[1
]}

Tsuzuki, Shunsuke ^{[2
]}

Shibahara, Ichiyo ^{[3
]}

Saito, Kuniaki ^{[4
]}

Shimoda, Yoshiteru ^{[1
]}

Tanaka, Kazuhiro ^{[5
]}

Yamaguchi, Shigeru ^{[6
]}

Natsumeda, Manabu ^{[7
]}

Matsutani, Tomoo ^{[8
]}

Hanihara, Mitsuto ^{[9
]}

Nakada, Mitsutoshi ^{[10
]}

Kuroda, Jun-Ichiro ^{[11
]}

Matsuda, Masahide ^{[12
]}

Yoshimoto, Koji ^{[13
]}

Yonezawa, Ushio ^{[14
]}

Sonoda, Yukihiko ^{[15
]}

Takano, Koji ^{[16
]}

Yonezawa, Hajime ^{[17
]}

Otani, Yoshihiro ^{[18
]}

Nakahara, Yukiko ^{[19
]}

Uchida, Masashi ^{[20
]}

Nonaka, Masahiro ^{[21
]}

Mineharu, Yohei ^{[22
]}

Kitamura, Yohei ^{[23
]}

Yamashita, Shinji ^{[24
]}

Yamauchi, Takahiro

Miyake, Yohei ^{[26
]}

Deguchi, Shoichi ^{[27
]}

Beppu, Takaaki ^{[28
]}

Tamura, Kaoru ^{[29
]}

Koizumi, Shinichiro ^{[30
]}

Hirose, Yuichi ^{[31
]}

Asano, Kenichiro ^{[32
]}

Hiruta, Ryo ^{[33
]}

Kinoshita, Manabu ^{[34
]}

Miyake, Keisuke ^{[35
]}

Nakayama, Noriyuki ^{[36
]}

Inoue, Akihiro ^{[37
]}

Ono, Takahiro ^{[38
]}

Sasaki, Takahiro ^{[39
]}

Akiyama, Yukinori ^{[40
]}

Fukami, Shinjiro ^{[41
]}

Yoshino, Atsuo ^{[42
]}

Kawanishi, Yu ^{[43
]}

Asanome, Taku ^{[44
]}

Yamaguchi, Takuhiro ^{[25
,45
]}

Takahashi, Masamichi ^{[46
]}

Yamasaki, Fumiyuki ^{[14
]}

Arakawa, Yoshiki ^{[22
]}

Narita, Yoshitaka ^{[46
]}

机构：

[1] Tohoku Univ, Grad Sch Med, Dept Neurosurg, 1-1 Seiryo Cho,Aoba Ku, Sendai, Japan

[2] Tokyo Womens Med Univ, Dept Neurosurg, Tokyo, Japan

[3] Kitasato Univ, Sch Med, Dept Neurosurg, Sagamihara, Japan

[4] Kyorin Univ Facil Med, Dept Neurosurg, Tokyo, Japan

[5] Kobe Univ, Grad Sch Med, Dept Neurosurg, Kobe, Japan

[6] Hokkaido Univ, Fac Med, Dept Neurosurg, Sapporo, Japan

[7] Niigata Univ, Brain Res Inst, Dept Neurosurg, Niigata, Japan

[8] Chiba Univ, Grad Sch Med, Dept Neurol Surg, Chiba, Japan

[9] Univ Yamanashi, Dept Neurosurg, Yamanashi, Japan

[10] Kanazawa Univ, Dept Neurosurg, Kanazawa, Japan

[11] Kumamoto Univ, Fac Life Sci, Dept Neurosurg, Kumamoto, Japan

[12] Univ Tsukuba, Inst Med, Dept Neurosurg, Tsukuba, Japan

[13] Kyushu Univ, Grad Sch Med Sci, Dept Neurosurg, Fukuoka, Japan

[14] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Neurosurg, Hiroshima, Japan

[15] Yamagata Univ, Fac Med, Dept Neurosurg, Yamagata, Japan

[16] Osaka Int Canc Inst, Dept Neurosurg, Osaka, Japan

[17] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Neurosurg, Kagoshima, Japan

[18] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg, Okayama, Japan

[19] Saga Univ, Fac Med, Dept Neurosurg, Saga, Japan

[20] St Marianna Univ, Sch Med, Dept Neurosurg, Kawasaki, Kanagawa, Japan

[21] Kansai Med Univ, Dept Neurosurg, Hirakara, Japan

[22] Kyoto Univ, Grad Sch Med, Dept Neurosurg, Kyoto, Japan

[23] Keio Univ, Sch Med, Dept Neurosurg, Tokyo, Japan

[24] Univ Miyazaki, Fac Med, Dept Clin Neurosci, Div Neurosurg, Miyazaki, Japan

[25] Univ Fukui, Fac Med Sci, Dept Neurosurg, Div Med, Fukui, Japan

[26] Yokohama City Univ, Grad Sch Med, Dept Neurosurg, Yokohama, Japan

[27] Shizuoka Canc Ctr, Div Neurosurg, Nagaizumi, Japan

[28] Iwate Med Univ, Dept Neurosurg, Shiwa, Japan

[29] Tokyo Med & Dent Univ, Dept Neurosurg, Tokyo, Japan

[30] Hamamatsu Univ, Sch Med, Dept Neurosurg, Hamamatsu, Japan

[31] Fujita Hlth Univ, Dept Neurosurg, Toyoake, Japan

[32] Hirosaki Univ, Grad Sch Med, Dept Neurosurg, Hirosaki, Japan

[33] Fukushima Med Univ, Dept Neurosurg, Fukushima, Japan

[34] Asahikawa Med Univ, Dept Neurosurg, Asahikawa, Hokkaido, Japan

[35] Kagawa Univ, Fac Med, Dept Neurol Surg, Kagawa, Japan

[36] Gifu Univ, Grad Sch Med, Dept Neurosurg, Gifu, Japan

[37] Ehime Univ, Sch Med, Dept Neurosurg, Toon, Japan

[38] Akita Univ, Grad Sch Med, Dept Neurosurg, Akita, Japan

[39] Wakayama Med Univ, Sch Med, Dept Neurol Surg, Wakayama, Japan

[40] Sapporo Med Univ, Dept Neurosurg, Sapporo, Japan

[41] Tokyo Med Univ, Dept Neurosurg, Tokyo, Japan

[42] Nihon Univ, Sch Med, Dept Neurol Surg, Tokyo, Japan

[43] Kochi Univ, Kochi Med Sch, Dept Neurosurg, Kochi, Japan

[44] Nakamura Mem Hosp, Brain Tumor Ctr, Dept Neurosurg, Sapporo, Japan

[45] Tohoku Univ, Grad Sch Med, Div Biostat, Sendai, Japan

[46] Natl Canc Ctr, Dept Neurosurg & Neurooncol, Tokyo, Japan

来源：

NEURO-ONCOLOGY ADVANCES | 2024年 / 6卷 / 01期

关键词：

Asian population; determinant of use; glioblastoma; survival; tumor-treating fields; PHASE-II; TEMOZOLOMIDE; CHEMOTHERAPY; RESECTION; EFFICACY; CRITERIA; EXTENT; TRIAL; WAFER;

D O I：

10.1093/noajnl/vdae176

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background. The EF-14 clinical trial demonstrated the safety and efficacy of tumor-treating fields (TTFields) for newly diagnosed glioblastoma. This study aimed to clarify the current status, safety, and efficacy of TTFields in Japanese patients who meet the EF-14 inclusion criteria. Methods. This was a multicenter retrospective cohort study. Background, treatment, and outcome data of patients who satisfied the inclusion criteria of the EF-14 trial were collected from 45 institutions across Japan. The rate, determinants, and current status of TTField use, including its safety and efficacy in terms of progression and survival, were retrospectively investigated. This study was conducted in accordance with the STROBE checklist. Results. Among the 607 patients enrolled, 70 were excluded due to progressive disease during radiation and temozolomide therapy, age > 80 years old, and Karnofsky Performance Status score of <70. Among the remaining 537 patients, 210 (39%) underwent TTField treatment. Multivariate analysis revealed younger age and spouse as a caregiver as significant factors for TTField use. The compliance rate of TTField use exceeded 75% in 60% of patients, with a median TTField usage duration of 11 months. Skin disorders requiring medical treatment occurred in 56% of patients. Multivariate Cox proportional hazards analysis in the whole series and propensity score-matched analysis revealed that TTField use was not a prognostic factor for progression-free survival (PFS) or overall survival (OS). Conclusions. TTField use did not have a substantial effect on either PFS or OS in Japanese patients with glioblastoma, despite compliance rates comparable to those observed in the EF-14.

引用

页数：11

共 50 条

[41] Dosimetric impact of a Tumor Treating Fields Device for glioblastoma Patients Undergoing simultaneous radiation Therapy
Li, Taoran
Shukla, Gaurav
Peng, Cheng
Lockamy, Virginia
Liu, Haisong
Shi, Wenyin
FRONTIERS IN ONCOLOGY, 2018, 8
[42] Survival, costs, and health care resource use by line of therapy in US Medicare patients with newly diagnosed glioblastoma: a retrospective observational study
Aly, Abdalla
Singh, Prianka
Korytowsky, Beata
Ling, You-Li
Kale, Hrishikesh P.
Dastani, Home B.
Botteman, Marc F.
Norden, Andrew D.
NEURO-ONCOLOGY PRACTICE, 2020, 7 (02) : 164 - 175
[43] Tumor treating fields for newly diagnosed high-grade glioma based on the criteria of 2021 WHO CNS5: A retrospective analysis of Chinese patients in a single center
Zhang, Li
Ren, Yanming
Peng, Youheng
Luo, Yong
Liu, Yanhui
Wang, Xiang
Yang, Yuan
Liu, Lei
Ai, Ping
Yang, Xiaoyan
Li, Yanchu
Mao, Qing
Wang, Feng
CANCER MEDICINE, 2024, 13 (11):
[44] Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial
Ram, Zvi
Kim, Chae-Yong
Hottinger, Andreas F.
Idbaih, Ahmed
Nicholas, Garth
Zhu, Jay-Jiguang
FRONTIERS IN ONCOLOGY, 2021, 11
[45] Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial
Kim, Chae-Yong
Paek, Sun Ha
Nam, Do-hyun
Chang, Jong-Hee
Hong, Yong-Kil
Kim, Jeong Hoon
Kim, Oh Lyong
Kim, Se-Hyuk
JOURNAL OF NEURO-ONCOLOGY, 2020, 146 (03) : 399 - 406
[46] Prognostic survival biomarkers of tumor-fused dendritic cell vaccine therapy in patients with newly diagnosed glioblastoma
Takei, Jun
Kamata, Yuko
Tanaka, Toshihide
Fukasawa, Nei
Gomisawa, Kazutaka
Satake, Mari
Mori, Ryosuke
Yamamoto, Yohei
Suzuki, Tomoya
Oda, Ayaka
Murahashi, Mutsunori
Fukuda, Takahiro
Shimoda, Masayuki
Murayama, Yuichi
Akasaki, Yasuharu
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (10) : 3175 - 3189
[47] Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study
Pinson, H.
Hallaert, G.
Van der Meulen, J.
Dedeurwaerdere, F.
Vanhauwaert, D.
Van den Broecke, C.
Van Dorpe, J.
Van Roost, D.
Kalala, J. P.
Boterberg, T.
JOURNAL OF NEURO-ONCOLOGY, 2020, 146 (01) : 55 - 62
[48] Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study
H. Pinson
G. Hallaert
J. Van der Meulen
F. Dedeurwaerdere
D. Vanhauwaert
C. Van den Broecke
J. Van Dorpe
D. Van Roost
J. P. Kalala
T. Boterberg
Journal of Neuro-Oncology, 2020, 146 : 55 - 62
[49] Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma
Song, Andrew
Bar-Ad, Voichita
Martinez, Nina
Glass, Jon
Andrews, David W.
Judy, Kevin
Evans, James J.
Farrell, Christopher J.
Werner-Wasik, Maria
Chervoneva, Inna
Ly, Michele
Palmer, Joshua D.
Liu, Haisong
Shi, Wenyin
JOURNAL OF NEURO-ONCOLOGY, 2020, 147 (03) : 653 - 661
[50] Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma: patterns of progression in a single institution pilot study
Ayesha S. Ali
Joseph Lombardo
Muneeb Z Niazi
Ryan C Miller
Iyad Alnahhas
Nina L Martinez
David W. Andrews
Kevin D Judy
Wenyin Shi
Journal of Neuro-Oncology, 2022, 160 : 345 - 350

← 1 2 3 4 5 →